Application of oncolytic virus or combination of oncolytic virus and gemcitabine and oxaliplatin to treatment of bile duct cancer
The invention relates to the technical field of medicines, and aims to provide application of a novel oncolytic virus VG161 in preparation of a medicine for treating bile duct cancer and application of the novel oncolytic virus VG161 combined with gemcitabine and oxaliplatin in preparation of a medicine group for treating bile duct cancer. The invention also provides a pharmaceutical composition for treating bile duct cancer, the pharmaceutical composition comprises a leading drug and a subsequent drug, the leading drug is composed of the oncolytic virus VG161 and pharmaceutically acceptable auxiliary materials, and the subsequent drug is composed of gemcitabine and oxaliplatin; through in-vitro cell tests, the VG161 single drug can effectively kill bile duct cancer cells, through in-vivo experiments of mice, the VG161 single drug can effectively treat tumors in a bile duct cancer mouse model, and after the VG161 is combined with a GEM + OXA scheme, the treatment effect is further improved. The method can be used for new auxiliary treatment of middle and advanced bile duct cancer patients with first-line treatment failure and boundary bile duct cancer excision patients, and has positive popularization and application values..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 13. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIANG TINGBO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-13, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 |
|---|
| Patentnummer: |
CN115463162 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016889363 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016889363 | ||
| 003 | DE-627 | ||
| 005 | 20231013134300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016889363 | ||
| 035 | |a (EPA)CN115463162 | ||
| 035 | |a (EPA)84363472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIANG TINGBO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of oncolytic virus or combination of oncolytic virus and gemcitabine and oxaliplatin to treatment of bile duct cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-13, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 | ||
| 520 | |a The invention relates to the technical field of medicines, and aims to provide application of a novel oncolytic virus VG161 in preparation of a medicine for treating bile duct cancer and application of the novel oncolytic virus VG161 combined with gemcitabine and oxaliplatin in preparation of a medicine group for treating bile duct cancer. The invention also provides a pharmaceutical composition for treating bile duct cancer, the pharmaceutical composition comprises a leading drug and a subsequent drug, the leading drug is composed of the oncolytic virus VG161 and pharmaceutically acceptable auxiliary materials, and the subsequent drug is composed of gemcitabine and oxaliplatin; through in-vitro cell tests, the VG161 single drug can effectively kill bile duct cancer cells, through in-vivo experiments of mice, the VG161 single drug can effectively treat tumors in a bile duct cancer mouse model, and after the VG161 is combined with a GEM + OXA scheme, the treatment effect is further improved. The method can be used for new auxiliary treatment of middle and advanced bile duct cancer patients with first-line treatment failure and boundary bile duct cancer excision patients, and has positive popularization and application values. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHEN YINAN |4 aut | |
| 700 | 0 | |a SONG WEI |4 aut | |
| 700 | 0 | |a YANG ZIFAN |4 aut | |
| 700 | 0 | |a GUO SIDA |4 aut | |
| 700 | 0 | |a WANG ZIJUN |4 aut | |
| 700 | 0 | |a LIN DANNI |4 aut | |
| 700 | 0 | |a LI YUWEI |4 aut | |
| 700 | 0 | |a LIANG XINGMEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 13. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:13 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84363472/publication/CN115463162A1?q=CN115463162 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 13 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 13 |c 12 | ||